Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Neuroendocrine × EC regimen × Clear all

Phase

Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Endocrine 1

Conditions

Small Cell Lung Carcinoma 2 Lung Neoplasms 1 Carcinoma, Neuroendocrine 1

Interventions

atezolizumab 2 Etoposide 2 Cisplatin 2 veliparib 1 tivozanib 1 surufatinib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 durvalumab 1 berzosertib 1 avelumab 1 Topotecan 1 Podophyllotoxin 1 Platinum 1 Paclitaxel 1 Nivolumab 1 Ipilimumab 1 Everolimus 1 EC regimen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

Phase 1/2 Recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡